Arimidex 1mg/tab 50 Tabletten by Beligas Pharmaceuticals

Usage

1. Calculate your last active compound's half-life and begin anastrozole only after circulating exogenous androgen levels have declined sufficiently — typically 2–5 days post-cycle for short esters, 14–21 days for long esters.
2. Start with 1 mg EOD to establish meaningful aromatase inhibition without driving estradiol below the physiological floor, which impairs libido and joint lubrication.
3. Monitor serum estradiol (E2) at the end of week one if possible; a reference-range E2 reading (typically 20–40 pg/mL in most lab protocols) confirms the dose is appropriate before proceeding.
4. Taper to 0.5 mg EOD once E2 is confirmed within range — this phase bridges anastrozole use into the SERM window without abrupt discontinuation.
5. Introduce your chosen SERM (tamoxifen, clomiphene, or enclomiphene) according to your protocol's schedule, maintaining the low-dose anastrozole overlap only if your protocol design calls for it.
6. Discontinue anastrozole by stepping down every 5–7 days rather than stopping immediately; this reduces the risk of estrogen rebound that can destabilise the HPG recovery achieved during the SERM phase.

Warnings

Frequently asked questions

What distinguishes modern PCT protocols from older, single-agent approaches?

Modern PCT protocols use a phased, multi-compound strategy rather than relying on one agent to perform every recovery function. The current standard separates the aromatase inhibition phase — where anastrozole controls estrogen elevation — from the SERM phase, where agents like tamoxifen or clomiphene reactivate HPG-axis signalling. This division of pharmacological labour produces a more controlled recovery environment than legacy monotherapy cycles allowed.

How does anastrozole fit specifically into a phase-structured PCT programme?

Anastrozole typically anchors the opening phase of a structured PCT programme, addressing estradiol levels during the androgen washout window. By occupying the aromatase enzyme (CYP19A1) before SERM therapy begins, it prevents the estrogen-dominant environment that would otherwise blunt gonadotropin response. Most evidence-informed protocols position anastrozole in weeks one and two, transitioning to a SERM once estradiol is within the physiological reference range.

What role do SERMs play alongside anastrozole in contemporary PCT design?

In contemporary PCT design, SERMs and aromatase inhibitors serve complementary but non-overlapping functions. Anastrozole controls estrogen synthesis at the aromatase enzyme level, while SERMs such as tamoxifen act as oestrogen receptor antagonists in hypothalamic tissue, directly stimulating LH and FSH output. Running both simultaneously throughout PCT is now considered less effective than sequencing them; anastrozole first, then SERM-led axis reactivation.

Can the 1 mg Beligas Arimidex tablets be split for lower-dose PCT sub-protocols?

Yes. The 1 mg tablet format is practical for splitting, allowing doses of approximately 0.5 mg — a common titration used in modern every-other-day anastrozole sub-protocols. Because tablet content is HPLC-confirmed at 1 mg, halving produces a pharmacologically predictable result, which is not reliably the case with tablets whose content has only been estimated from manufacturing inputs rather than analytically verified.

How should Beligas Arimidex tablets be stored to maintain potency across a full 50-tablet PCT cycle?

Store the tablets in their original packaging at room temperature (15–25 °C), away from direct light, moisture, and heat sources. Anastrozole is chemically stable under these conditions; the primary degradation risk is prolonged humidity exposure, which can affect tablet integrity over extended storage. A 50-tablet pack covers most standard PCT cycles at typical dosing, so storage duration is usually not a concern if tablets are used within the same protocol period they were acquired for. (2) angle_used

Manufacturer

The anastrozole content in every Beligas Pharmaceuticals Arimidex batch is subject to a release criterion that cannot be satisfied by input-weight calculations alone: the 1 mg per tablet figure must be returned as a chromatographically confirmed value before distribution clearance is granted. That confirmation comes through HPLC (High-Performance Liquid Chromatography), which isolates the anastrozole peak from excipient and process-related matrix components and measures it against certified pharmacopoeial reference standards on a lot-by-lot basis. For a PCT ancillary where the therapeutic window is comparatively narrow — the difference between effective aromatase suppression and over-suppression is a fraction of a milligram — this lot-specific verification is operationally significant rather than procedural formality. Complementing the HPLC step, each batch passes LAL (Limulus Amebocyte Lysate) endotoxin screening and is produced within a cGMP-compliant manufacturing environment, ensuring that what reaches the end user is not only correctly dosed but produced under conditions consistent with pharmaceutical-grade ancillary standards.